Neurogene Inc.
NGNENASDAQHealthcare● Active
$27.56
+$1.07(+4.04%)
Market Cap$435500364
P/E Ratio—
52W High$37.266
52W Low$14.65
Neurogene Inc. (NGNE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NGNE · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$1.39
Est. -$1.30 · -7.2%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS
NGNE reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.00B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.00B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$1.43 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$1.30 | -$1.39 | -7.2% | — | — | — |
| ▲ Q1 FY2026 | Mar 24, 2026 | -$1.24 | -$1.12 | +9.6% | — | — | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$1.26 | -$0.99 | +21.4% | — | — | — |
| ▲ Q3 FY2025 | Aug 11, 2025 | -$1.15 | -$1.05 | +8.7% | — | — | — |
| ▼ Q2 FY2025 | May 9, 2025 | -$1.05 | -$1.08 | -2.9% | — | — | — |
| ▲ Q1 FY2025 | Mar 24, 2025 | -$1.04 | -$0.99 | +4.8% | — | — | — |
| ▲ Q4 FY2024 | Nov 18, 2024 | -$1.22 | -$1.19 | +2.5% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$1.43
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$1.39
EPS Est.
-$1.30
EPS Surpr.
-7.2%
Revenue
—
Q1 FY2026
Mar 24, 2026Beat
EPS Actual
-$1.12
EPS Est.
-$1.24
EPS Surpr.
+9.6%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.99
EPS Est.
-$1.26
EPS Surpr.
+21.4%
Revenue
—
Q3 FY2025
Aug 11, 2025Beat
EPS Actual
-$1.05
EPS Est.
-$1.15
EPS Surpr.
+8.7%
Revenue
—
Q2 FY2025
May 9, 2025Miss
EPS Actual
-$1.08
EPS Est.
-$1.05
EPS Surpr.
-2.9%
Revenue
—
Q1 FY2025
Mar 24, 2025Beat
EPS Actual
-$0.99
EPS Est.
-$1.04
EPS Surpr.
+4.8%
Revenue
—
Q4 FY2024
Nov 18, 2024Beat
EPS Actual
-$1.19
EPS Est.
-$1.22
EPS Surpr.
+2.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.57 | $-1.57 | $-1.57 | 2 |
| Q3 FY2027 | $-1.53 | $-1.53 | $-1.53 | 2 |
| Q2 FY2027 | $-1.50 | $-1.50 | $-1.50 | 2 |
| Q1 FY2027 | $-1.47 | $-1.47 | $-1.47 | 2 |
| Q4 FY2026 | $-1.40 | $-1.40 | $-1.40 | 4 |
| Q3 FY2026 | $-1.76 | $-1.37 | $-0.99 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -7.2% | $30.89 | $31.54 | +2.10% |
| ▲ Q1 FY2026 | Mar 24, 2026 | +9.6% | $19.36 | $20.90 | +7.95% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +21.4% | $31.08 | $26.49 | -14.77% |
| ▲ Q3 FY2025 | Aug 11, 2025 | +8.7% | $21.22 | $20.35 | -4.10% |
| ▼ Q2 FY2025 | May 9, 2025 | -2.9% | $15.00 | $14.73 | -1.80% |
| ▲ Q1 FY2025 | Mar 24, 2025 | +4.8% | $14.21 | $13.96 | -1.76% |
| ▲ Q4 FY2024 | Nov 18, 2024 | +2.5% | $34.52 | $19.82 | -42.58% |
| ▼ Q3 FY2024 | Aug 9, 2024 | -6.9% | $36.55 | $35.59 | -2.63% |
Q2 FY2026+2.10%
Report Date
May 12, 2026
EPS Beat/Miss
-7.2%
Price Before
$30.89
Price After
$31.54
Q1 FY2026+7.95%
Report Date
Mar 24, 2026
EPS Beat/Miss
+9.6%
Price Before
$19.36
Price After
$20.90
Q4 FY2025-14.77%
Report Date
Nov 13, 2025
EPS Beat/Miss
+21.4%
Price Before
$31.08
Price After
$26.49
Q3 FY2025-4.10%
Report Date
Aug 11, 2025
EPS Beat/Miss
+8.7%
Price Before
$21.22
Price After
$20.35
Q2 FY2025-1.80%
Report Date
May 9, 2025
EPS Beat/Miss
-2.9%
Price Before
$15.00
Price After
$14.73
Q1 FY2025-1.76%
Report Date
Mar 24, 2025
EPS Beat/Miss
+4.8%
Price Before
$14.21
Price After
$13.96
Q4 FY2024-42.58%
Report Date
Nov 18, 2024
EPS Beat/Miss
+2.5%
Price Before
$34.52
Price After
$19.82
Q3 FY2024-2.63%
Report Date
Aug 9, 2024
EPS Beat/Miss
-6.9%
Price Before
$36.55
Price After
$35.59
Avg Beat Reaction-11.05%
Avg Miss Reaction-0.78%
Beat Rate5 / 8 quarters
Largest Move-42.58% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NGNE ends December
Neurogene Inc. (NGNE) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-1.39 — missing the analyst consensus of $-1.30 by -7.2%. The next NGNE earnings date is expected around September 1, 2026.
Each quarter, investors track NGNE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NGNE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NGNE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NGNE earnings · 5 questionsNeurogene Inc.'s next earnings report is expected around September 1, 2026. NGNE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NGNE historically reports after market close (AMC).
NGNE earnings datewhen is NGNE earningsNGNE next earnings datewhen does NGNE report earningsNGNE earnings calendar
▸ Source: FMP · Neurogene Inc. SEC filings · US GAAP · Neurogene Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026